Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer

Trial Profile

A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 26 Sep 2018 Results (data cut off 21 Feb 2018; n=48) demonstrating Tislelizumab well tolerated in patients with advanced lung cancer presented at the 19th World Conference on Lung Cancer
    • 20 Sep 2018 According to a BeiGene media release, data were presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO).
    • 20 Sep 2018 Preliminary data presented in a BeiGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top